Search
for
Sort by
Research 151–180 of 1000+
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Mimosine Dipeptide Enantiomsers: Improved Inhibitors against Melanogenesis and Cyclooxygenase
- Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
- Ritlecitinib: First Approval
- Adverse effects of common medications on male fertility
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Dermatologic Reactions to Targeted Therapy
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Dermatologic Adverse Events from Cancer Treatments
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- Sorafenib-induced Facial Acneiform Eruption
- Enzyme Inhibitors from Gorgonians and Soft Corals
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Wound Healing: A Cellular Perspective
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- JAK Inhibitors for Treatment of Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
- Roles of tumor suppressors in regulating tumor-associated inflammation